Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.10 | 41.40 | -0.46% |
| CAC 40 | 8,306.33 | 131.56 | -1.56% |
| DAX 40 | 24,850.46 | 304.95 | -1.21% |
| Dow JONES (US) | 51,735.08 | 483.50 | -0.93% |
| FTSE 100 | 10,650.83 | 66.14 | -0.62% |
| HKSE | 25,210.81 | 318.15 | 1.28% |
| NASDAQ | 25,249.55 | 441.35 | -1.72% |
| Nikkei 225 | 66,422.60 | 307.00 | 0.46% |
| NZX 50 Index | 13,795.31 | 32.13 | 0.23% |
| S&P 500 | 7,429.43 | 69.53 | -0.93% |
| S&P/ASX 200 | 8,839.00 | 38.60 | -0.43% |
| SSE Composite Index | 3,876.78 | 9.74 | 0.25% |